FDA-cleared AI-powered ECG platform for cardiac monitoring and arrhythmia detection
AliveCor builds an FDA-cleared ECG platform with deep learning for detecting arrhythmias like atrial fibrillation. The tech stack—Go, Java, React, Kubernetes, AWS, PostgreSQL—is structured for high-availability microservices and mobile-first delivery across iOS and Android. The hiring mix skews sales-heavy (5 roles) relative to engineering (4), paired with active projects around enterprise client implementation, partner onboarding, and AI integration, signaling a shift from pure consumer adoption toward hospital and healthcare provider sales channels.
Notable leadership hires: Sales Director, Sales Lead
AliveCor develops a personal ECG monitoring platform that uses AI to detect cardiac arrhythmias, including atrial fibrillation, bradycardia, tachycardia, and supraventricular ectopy. The KardiaMobile 6L device provides instant ECG analysis accessible to both consumers and clinicians. Beyond the consumer device, AliveCor operates an enterprise platform that allows healthcare providers and third-party organizations to integrate ECG monitoring and patient management into their workflows. The company is based in Mountain View and maintains HIPAA compliance, ISO 27001, and SOC 2 Type 2 certifications. Revenue streams span direct-to-consumer sales and B2B enterprise partnerships with hospitals and healthcare systems.
AliveCor uses Go, Java, React, and Python for core services, containerized via Docker and Kubernetes on AWS. The backend is built on PostgreSQL and DynamoDB for data persistence, with Redis for caching. Mobile apps run on iOS and Android.
KardiaMobile 6L is an FDA-cleared ECG device that detects seven cardiac conditions: atrial fibrillation, bradycardia, tachycardia, sinus rhythm with supraventricular ectopy, sinus rhythm with premature ventricular contractions, sinus rhythm with wide QRS, and normal sinus rhythm.
Other companies in the same industry, closest in size